Tonix Pharmaceuticals TNX-1500 Transplant & Autoimmune 2024

Tonix Pharmaceuticals presents TNX-1500, a next-generation anti-CD40L antibody candidate designed to prevent organ transplant rejection and treat autoimmune disorders. The Phase 1 study has completed with pharmacokinetic results pending, with planned Phase 2 initiation in kidney transplant recipients. TNX-1500 addresses safety limitations of prior-generation candidates through selective Fc region modification.